Faes Farma


Growth in the anti-histamine space has been called into question

29/06/20 -"As many people have been either staying indoors or wearing masks outdoors, there has been a reduction in pollen allergies, which in turn has put pressure on sales for Faes’ principal value creator, ..."

Pages
58
Language
English
Published on
29/06/20
You may also be interested by these reports :
09/07/20
A couple of months after our last teaser (FAES FARMA’S DREAM RUN OVER?) in October 2019, Faes Farma (Reduce, Spain) touched a new lifetime high – led ...

08/07/20
Following our headline ’Settled!?’ on 25/06/2020, our new headline looks a bit revanchist as we had expected that Bayer ‘just’ wanted to manage ...

03/07/20
With CHF13bn ($14bn) annual sales, Roche is a dominant force in the global diagnostics market. Interestingly, in recent years, most diagnostics ...

03/07/20
With increasing demand for Roche’s COVID-19 tests – particularly molecular tests, the annual top-line should benefit by CHF1.5bn. Moreover, taking ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO